Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 92

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 92
---
 Receptor Blocker (ARB):

A Potent Combination Therapy to a Wide Range of Cancer Therapies</div>

The Company’s next drug candidate is
another novel nanoparticles-based formulation of angiotensin receptor blockers (ARBs), also known as AT1 receptor blockers (AT1) for
intravenous (IV) administration.

The Company holds an exclusive option to license
for a nanoparticle-based Angiotensin Receptor Blocker (ARB) formulation, with the right to exercise the option to obtain an exclusive,
worldwide license for the development, manufacturing, and commercialization of products incorporating the underlying technology. The
option must be exercised within 90 days following receipt of the final scientific report, after which the parties have up to 120 days
to negotiate the definitive licensing agreement. As part of this process, the Company plans to conduct large animal safety studies in
the fourth quarter of 2025 to support its decision on whether to exercise the licensing option and finalize the related terms. If results
do not meet safety thresholds, we do not intend to exercise the option.. If no agreement is reached within the negotiation period, Yissum
shall have no further obligations to the Company with respect to the technology.

ARBs is a class of drugs that block the Angiotensin
II Type 1 receptor (AT1), which is involved in the regulation of blood pressure, fluid balance, and inflammation. ARBs have been widely
used for the treatment of hypertension, heart failure, and diabetic nephropathy. Several recent studies have shown that ARBs may have
certain anti-cancer efficacy. Among other, ARBs can inhibit proliferation, migration, invasion, and angiogenesis of tumor cells, as well
as induce apoptosis and autophagy. ARBs may also modulate the immune response by affecting the polarization and activation of macrophages,
T cells, and natural killer cells.

Novel formulation of Nanoparticles-based ARB (nano-ARB)
was designed to improve the therapeutic efficacy of chemotherapy and biological treatments, such as antibodies and immune checkpoint inhibitors
(a class of anti-cancer immune therapies) for solid cancers. Solid cancers, such as breast, lung, colon, and prostate cancers, present
a formidable challenge to oncologists, as they are often resistant to existing treatments and have poor prognosis. One major obstacle
lies in the complex tumor microenvironment (TME), which consists of various cellular and non-cellular components that interact with each
other and with the tumor cells. The